We considered the diagnosis of CD56-positive AML with aberrant expression of lymphoid antigens, since the leukaemic cells expressed CD56+, heterogeneous CD33+ and weak CD117+, but CD4 and CD123 positivity, added to the clinical presentation of the patient, made it unlikely [13]. The gene discussed is NCAM1; the disease is acute myeloid leukemia.